Zencurix Obtains MFDS Manufacturing Approval for Thyroid Cancer Mutation In Vitro Diagnostic Kit

[Asia Economy Reporter Lee Gwan-joo] GenCurix announced on the 7th that it has obtained manufacturing approval from the Ministry of Food and Drug Safety for the thyroid cancer mutation in vitro diagnostic kit 'Droplex BRAF Mutation Test.'

This kit is an in vitro diagnostic medical device that detects the presence of mutations in the BRAF gene 'Codon 600' from DNA derived from tissues of patients with papillary thyroid carcinoma (PTC) using digital PCR technology.